Summary & Overview
HCPCS J9348: Naxitamab-gqgk Injection, 1 mg
HCPCS Level II code J9348 denotes the injection of naxitamab-gqgk, billed per 1 mg. Naxitamab-gqgk is a monoclonal antibody indicated for certain oncologic indications and is administered as an injectable biologic in outpatient infusion centers, hospital outpatient departments, or clinic settings. This code matters nationally because it standardizes billing for a high-cost specialty oncology drug and impacts coverage, prior authorization workflows, and cost management across major payers.
Key payers covered in this overview include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise explanation of the code’s clinical and billing context, typical sites of service, and which payers are commonly involved. The publication also outlines expected analytical content such as utilization benchmarks, coverage and prior authorization considerations, and policy updates relevant to specialty oncology drug billing.
This summary provides a national perspective on clinical context and administrative implications for naxitamab-gqgk billing. Data not available in the input is noted where specific payer policy details, taxonomies, ICD-10 pairings, and related codes would otherwise be listed.
Billing Code Overview
HCPCS Level II code J9348 represents the drug injection naxitamab-gqgk, billed per 1 mg. This code is used for administration of the specified monoclonal antibody formulation.
Service Type: Drug administration / Injectable biologic
Typical Site of Service: Outpatient infusion center, hospital outpatient department, or clinic setting
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a pediatric or young adult with high-risk relapsed/refractory neuroblastoma receiving targeted immunotherapy. The patient presents to an outpatient oncology infusion center or a hospital-based infusion suite for administration of J9348 (naxitamab-gqgk) dosed by milligram. Pre-infusion workflow includes verification of prescription, weight-based dose calculation, allergy review, baseline vital signs and pain assessment, and placement of peripheral IV or use of an implanted central venous catheter. Infusion nurses prepare the medication under sterile conditions and perform premedication per protocol (antiemetic, antipyretic, antihistamine) and evaluate for eligibility for outpatient infusion versus inpatient monitoring based on prior infusion reactions. During infusion, nurses perform continuous monitoring for infusion-related reactions, transient hypertension, pain, or neurotoxic effects; appropriate emergency medications and equipment are available. Post-infusion monitoring includes vital signs, observation for delayed hypersensitivity, documentation of total mg administered (and any residual discarded), and communication of dose and administration details to the treating pediatric oncologist and the patient/family. Billing reflects the exact milligrams administered using J9348 with applicable modifiers (for example, JW if discarded vial contents are reported).
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|